%D8%A8%D8%B1%DB%8C%D9%86_%D8%B2%D9%88%D9%84%D8%A7%D9%85%DB%8C%D8%AFBrinzolamidBrinsolamidBrinzolamidBrinzolamideBrinzolamida%D8%A8%D8%B1%DB%8C%D9%86%D8%B2%D9%88%D9%84%D8%A7%D9%85%DB%8C%D8%AF%E3%83%96%E3%83%AA%E3%83%B3%E3%82%BE%E3%83%A9%E3%83%9F%E3%83%89Brynzolamid%D0%91%D1%80%D0%B8%D0%BD%D0%B7%D0%BE%D0%BB%D0%B0%D0%BC%D0%B8%D0%B4BrinzolamidBrinzolamidQ411517
about
P3781
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular HypertensionPatient Preference Comparison of AZARGA Versus COSOPT in Patients With GlaucomaThe Effects of the Water Drinking Test on Intraocular PressureEarlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for GlaucomaBrinzolamide for the Treatment of Chronic Central Serous ChorioretinopathyBREMEN Eye Drops Versus Combigan and Azopt for Open-angle Glaucoma or Intraocular HypertensionA Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%Patient Preference Comparison of AZARGA Versus COSOPTFixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular HypertensionThree Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus SyndromeBrinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionTherapeutic Equivalence Study of Generic Brinzolamide vs AzoptBrinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionSafety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyComparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular HypertensionComparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin AnalogsSafety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular HypertensionSIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)Stop Retinal Ganglion Cell Dysfunction StudyEffect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueEffect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OHAssessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in BrazilAZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular PressureAssessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin AmericaEfficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/TimololSafety and Efficacy of Brinzolamide/Brimonidine Fixed CombinationCircadian Ocular Perfusion Pressure and Ocular Blood FlowA Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a ProstaglandinAzopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPTEffect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After PhacoemulsificationBioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both EyesEfficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
P4844
Q61932880-E5EDF411-5D4E-4740-9869-749373FA4A62Q61955591-545F9633-FCD7-4850-B314-2782844CB9F8Q61956722-5BB53BDA-EED2-4E1E-BDC3-FA0C964F9479Q61980747-95606C3B-82B2-43DA-8169-C3708F950F83Q62811325-407C1C02-075C-4723-B2D8-81248DB5E97FQ63011543-D10E0559-3AEA-45B5-92E5-D6DCC1DCAEB8Q63321025-2AB786E1-0570-41B4-ABF9-F98AA67B4077Q63334867-5E3373AC-5440-4B37-BA4B-B907E45C003FQ63336334-62736D18-F59F-43AC-91BF-C249D0251998Q63338805-4200B866-79ED-420E-A2F3-3ED1C818E112Q63338895-E85C6F53-445C-4B29-ADCF-54A69767F307Q63339006-62B3AEE5-902A-4EF5-9B83-60C855516E82Q63339265-F7C8CBF6-B821-43C6-94AD-E44F90179860Q63580203-4FF971EB-04AE-4374-8F78-290A7AE016DDQ63813623-6CD171A4-337E-4BAE-8BBE-30D85B76C173Q63817057-C71C13E8-8085-4304-A01C-F107A0E096A4Q63832839-2AABCBE4-A8EA-493A-867C-FEB58D5A1494Q64046905-D657C92C-B24E-40C7-963E-6DE2DDA685A9Q64123071-F2D6912F-31FB-4DBB-88E3-0095B1CC0A4BQ64352718-67DD1B2F-244B-49FA-928E-4AF710804EC7Q64395725-41A1B292-4FDF-46B0-BD21-2BE96420E7C5Q64397384-F7BD035C-CF35-432A-9228-116048D265D2Q64612736-ACCABFAD-AC22-4178-A222-BB59FE838758Q64612739-0825D46C-DE94-4AB6-A02F-9655F6DB39E2Q64638283-8AF4282F-F88F-4B77-95F2-3D7FCB9F7591Q64645980-EBFC5121-160A-4A30-8EDE-C53607C58B5BQ64646977-3E6C4B51-85B4-4E25-8FBA-DEB0AB609F1FQ64647405-7F60F4D5-B493-4BD1-ADD9-9CE6F2F20E15Q64648489-EDBC1ADA-D2FB-4EE0-80E1-F176A2EF27C3Q64662952-5547D943-77D2-454C-9A84-959D155FB0B9Q64663643-E9CC8E3D-6934-45E1-B182-CAF8DD0F625CQ64709084-8AA04454-220B-47B6-A945-1CA368BEC892Q64715186-13EEB809-BEE6-4A99-A777-CEB1A4486515Q64715509-E6BE48A0-96AE-400F-BF6D-D18C1EE6C1ECQ64716365-8F2DAA15-7404-4A13-A044-290C69AA84C7Q64716367-D8297591-671C-400C-8163-15E252C4E988Q64802104-5126CA01-CB56-4CE9-A1BF-B0B38812416DQ65337671-46B18EDE-8D0A-4E98-A3AF-4D7FA24DDBADQ65349622-2F25380F-C92D-4C19-8A0B-FD70E5D42460Q65352839-02862BD2-E529-4E79-9B06-9D6C40A017CC
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Brinzolamid
@bs
Brinzolamid
@de
Brinzolamid
@sh
Brinzolamid
@sr
Brinzolamida
@es
Brinzolamide
@vi
Brynzolamid
@pl
brinsolamid
@cy
brinzolamid
@nn
brinzolamide
@en
type
label
Brinzolamid
@bs
Brinzolamid
@de
Brinzolamid
@sh
Brinzolamid
@sr
Brinzolamida
@es
Brinzolamide
@vi
Brynzolamid
@pl
brinsolamid
@cy
brinzolamid
@nn
brinzolamide
@en
altLabel
AL-4862
@cy
AL-4862
@en
Azopt®
@cy
Azopt®
@en
Brinzolamide
@en
prefLabel
Brinzolamid
@bs
Brinzolamid
@de
Brinzolamid
@sh
Brinzolamid
@sr
Brinzolamida
@es
Brinzolamide
@vi
Brynzolamid
@pl
brinsolamid
@cy
brinzolamid
@nn
brinzolamide
@en